Antiphospholipid antibodies in patients with COVID‐19: A relevant observation?

Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, N Engl J Med, 382, 727, 10.1056/NEJMoa2001017

Han, 2020, Prominent changes in blood coagulation of patients with SARS‐CoV‐2 infection, Clin Chem Lab Med, 58, 1116, 10.1515/cclm-2020-0188

Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J Thromb Haemost, 18, 844, 10.1111/jth.14768

Chen, 2020, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet, 395, 507, 10.1016/S0140-6736(20)30211-7

Helms, 2020, High risk of thrombosis in patients with severe SARS‐CoV‐2 infection: a multicenter prospective cohort study, Intensive Care Med, 46, 1089, 10.1007/s00134-020-06062-x

Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 Novel coronavirus‐infected pneumonia in Wuhan, China, JAMA, 323, 1061, 10.1001/jama.2020.1585

Zhang, 2020, Coagulopathy and antiphospholipid antibodies in patients with Covid‐19, N Engl J Med, 382, 10.1056/NEJMc2007575

Bowles, 2020, Lupus anticoagulant and abnormal coagulation tests in patients with Covid‐19, N Engl J Med, 383, 288, 10.1056/NEJMc2013656

Harzallah, 2020, Lupus anticoagulant is frequent in patients with Covid‐19, J Thromb Haemost

Devreese, 2018, Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH, J Thromb Haemost, 16, 809, 10.1111/jth.13976

Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, 295, 10.1111/j.1538-7836.2006.01753.x

Devreese, 2014, Antiphospholipid antibody testing and standardization, Int J Lab Hematol, 36, 352, 10.1111/ijlh.12234

Devreese, 2020, Testing for antiphospholipid antibodies: advances and best practices, Int J Lab Hematol, 42, 49, 10.1111/ijlh.13195

Devreese, 2020, How to interpret antiphospholipid laboratory tests, Curr Rheumatol Rep, 22, 10.1007/s11926-020-00916-5

Uthman, 2002, Viral infections and antiphospholipid antibodies, Semin Arthritis Rheum, 31, 256, 10.1053/sarh.2002.28303

Galli, 2007, Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study, Blood, 110, 1178, 10.1182/blood-2007-01-066043

Kelchtermans, 2016, IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis, J Thromb Haemost, 14, 1530, 10.1111/jth.13379

Chayoua, 2020, The (non‐)sense of detecting anti‐cardiolipin and anti‐beta2glycoprotein I IgM antibodies in the antiphospholipid syndrome, J Thromb Haemost, 18, 169, 10.1111/jth.14633

Pengo, 2012, What have we learned about antiphospholipid syndrome from patients and antiphospholipid carrier cohorts?, Semin Thromb Hemost, 38, 322, 10.1055/s-0032-1304719

Devreese, 2014, Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH, J Thromb Haemost, 12, 792, 10.1111/jth.12537

Meijide, 2013, The clinical relevance of IgA anticardiolipin and IgA anti‐beta2 glycoprotein I antiphospholipid antibodies: a systematic review, Autoimmun Rev, 12, 421, 10.1016/j.autrev.2012.08.002

Sciascia, 2014, Anti‐prothrombin (aPT) and anti‐phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome, A systematic review. Thromb Haemost, 111, 354, 10.1160/TH13-06-0509

Radin, 2020, Antiphosphatidylserine/Prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome, Thromb Haemost, 120, 592, 10.1055/s-0040-1705115

Pengo, 2009, Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis, J Thromb Haemost, 7, 1737, 10.1111/j.1538-7836.2009.03555.x

Devreese, 2015, Mixing studies in lupus anticoagulant testing are required at least in some type of samples, J Thromb Haemost, 13, 1475, 10.1111/jth.13020

Schouwers, 2010, Lupus Anticoagulant (LAC) testing in patients with inflammatory status: does C‐reactive protein interfere with LAC test results?, Thromb Res, 125, 102, 10.1016/j.thromres.2009.09.001

De Kesel, 2019, The effect of unfractionated heparin, enoxaparin and danaparoid on lupus anticoagulant testing. Can activated carbon eliminate false positive results?, Res Pract Thromb Haemost, 4, 161, 10.1002/rth2.12264

Tripodi, 2020, Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the, J Thromb Haemost, 18, 1569, 10.1111/jth.14846

Chayoua, 2019, Detection of anti‐cardiolipin and anti‐beta2glycoprotein I antibodies differs between platforms without influence on association with clinical symptoms, Thromb Haemost, 119, 797, 10.1055/s-0039-1679901

Chayoua, 2018, Identification of high thrombotic risk triple‐positive antiphospholipid syndrome patients is dependent on anti‐cardiolipin and anti‐beta2glycoprotein I antibody detection assays, J Thromb Haemost, 16, 2016, 10.1111/jth.14261

Chayoua, 2019, Anti‐cardiolipin and anti‐β2glycoprotein I IgA along with the current criteria does not have an added value in screening for clinical symptoms of the antiphospholipid syndrome, Res Pract Thromb Haemost, 3, 687

Devreese, 2015, Interference of C‐reactive protein with clotting times, Clin Chem Lab Med, 53, e141, 10.1515/cclm-2014-0906

Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J Thromb Haemost, 18, 1094, 10.1111/jth.14817

Cui, 2020, Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia, J Thromb Haemost, 18, 1421, 10.1111/jth.14830

Klok, 2020, Incidence of thrombotic complications in critically ill ICU patients with COVID‐19, Thromb Res, 191, 145, 10.1016/j.thromres.2020.04.013

Thachil, 2020, ISTH interim guidance on recognition and management of coagulopathy in COVID‐19, J Thromb Haemost, 18, 1023, 10.1111/jth.14810

Thachil, 2020, Laboratory haemostasis monitoring in COVID‐19, J Thromb Haemost, 18, 2058, 10.1111/jth.14866

Goeijenbier, 2012, Review: viral infections and mechanisms of thrombosis and bleeding, J Med Virol, 84, 1680, 10.1002/jmv.23354

Antoniak, 2014, Multiple roles of the coagulation protease cascade during virus infection, Blood, 123, 2605, 10.1182/blood-2013-09-526277

Barrett, 2020, ISTH interim guidance on recognition and management of coagulopathy in COVID‐19: A Comment, J Thromb Haemost, 18, 1023, 10.1111/jth.14810

Kollias, 2020, Thromboembolic risk and anticoagulant therapy in COVID‐19 patients: emerging evidence and call for action, Br J Haematol, 189, 846, 10.1111/bjh.16727

Iba, 2020, Coagulopathy of coronavirus disease 2019, Crit Care Med, 48, 1358, 10.1097/CCM.0000000000004458

Pengo, 2005, Antibody profiles for the diagnosis of antiphospholipid syndrome, Thromb Haemost, 93, 1147, 10.1160/TH04-12-0839

Pengo, 2018, Laboratory diagnostics of antiphospholipid syndrome, Semin Thromb Hemost, 44, 439, 10.1055/s-0037-1601331

Pengo, 2013, Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipid antibody profile, J Thromb Haemost, 11, 1527, 10.1111/jth.12264

Pengo, 2010, Clinical course of high‐risk patients diagnosed with antiphospholipid syndrome, J Thromb Haemost, 8, 237, 10.1111/j.1538-7836.2009.03674.x

Sciascia, 2012, Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities, J Thromb Haemost, 10, 2512, 10.1111/jth.12014

Mustonen, 2014, Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study, Lupus, 23, 1468, 10.1177/0961203314545410

Pengo, 2018, Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns, Thromb Res, 172, 172, 10.1016/j.thromres.2018.11.003

Goldman‐Mazur, 2019, High detection rates of antithrombin deficiency and antiphospholipid syndrome in outpatients aged over 50years using the standardized protocol for thrombophilia screening, Thromb Res, 176, 67, 10.1016/j.thromres.2019.02.008

Urbanus, 2009, Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case‐control study, Lancet Neurol, 8, 998, 10.1016/S1474-4422(09)70239-X

Mattia, 2018, Clinical and laboratory characteristics of isolated lupus anticoagulants, Thromb Res, 165, 51, 10.1016/j.thromres.2018.03.008

Ware, 2000, The acute respiratory distress syndrome, N Engl J Med, 342, 1334, 10.1056/NEJM200005043421806

Litvinova, 2018, Prevalence and significance of non‐conventional antiphospholipid antibodies in patients with clinical APS criteria, Front Immunol, 9, 2971, 10.3389/fimmu.2018.02971

Pengo, 2018, Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): a personal perspective, Thromb Res, 169, 35, 10.1016/j.thromres.2018.07.011

Pengo, 2011, Incidence of a first thromboembolic event in asymptomatic carriers of high‐risk antiphospholipid antibody profile: a multicenter prospective study, Blood, 118, 4714, 10.1182/blood-2011-03-340232

Abdel‐Wahab, 2018, Risk of developing antiphospholipid antibodies following viral infection: a systematic review and meta‐analysis, Lupus, 27, 572, 10.1177/0961203317731532

Cruz‐Tapias, 2012, Infections and vaccines in the etiology of antiphospholipid syndrome, Curr Opin Rheumatol, 24, 389, 10.1097/BOR.0b013e32835448b8

Schreiber, 2018, Antiphospholipid syndrome, Nat Rev Dis Primers, 4, 18005, 10.1038/nrdp.2018.5

Levi, 2010, Inflammation and coagulation, Crit Care Med, 38, S26, 10.1097/CCM.0b013e3181c98d21

Pearson, 2003, Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the centers for disease control and prevention and the American Heart Association, Circulation, 107, 499, 10.1161/01.CIR.0000052939.59093.45